Anti-inflammatory compositions and methods
First Claim
Patent Images
1. A compound of formula I:
-
R1—
NH—
CO—
NH-Q-R2
(I)or a pharmaceutically acceptable salt thereofwhereinR1 s a lower C2–
C5 alkyl group, straight or branched chain and optionally substituted by an amino group of formula —
NR3R4, wherein R3 and R4 are independently H, or C1–
C3 alkyl group;
Q is either a bond or a divalent C1–
C5 straight or branched alkyl or aikenyl group;
R2 is one of the following groupsa. C5–
C10 heteroaryl group selected from furanyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, dithiolyl, oxathiolyl, isoxazolyl, piridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoquinolinyl, benzimidazolyl, benzoxaziyl, benzothiadiazolyl nanhthyridinyl, pyrido[3,4-b]pyridinyl, pyrido[3,2-b]b pyridinyl, pyrido[4,3-b]hyridinyl, and 4-aminopyrazolo[3,4d]pyrimidinylb. C5–
C10 heterocyclic group selected from piperazyl, tetahydrofuranyl, dioxanyl, wherein the heteroaryl, or heterocyclic ring is unsubstituted or substituted by one or more of the following groupsi. R5, —
CN, Halogen, OR5, —
COR5, —
CO2R5, OCF3, —
CONH2, —
SO2NH2, and NO2, wherein R5 is a C1 to C4 straight or branched alkyl group, andc. N6R 7, wherein R6 and R7 aretogether with the N forming a 5 or 6 membered monocyclic ring having one or more ring positions occupied by another N, S, or O, wherein the heteroaryl ring thus formed is unsubstituted or substituted by one or more of the following groups1. R5, —
CN, halogen, OR5, —
COR5, —
CO2R5, OCF3, —
CONH2, —
SO2NH2,2. C1–
C5 aikyl or alkylene group substituted by an aryl group, and3. C6 or C10 aryl or heteroaryl group unsubstituted or substituted by one ore more of R5, CF3, and halogen, wherein the aryl or hetero aryl may be a pending group off one position of, or a fused with, the NR6R7 ring.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus. The compositions comprise disubstituted ureas of Formulas I, II, III or IV:
R1—NH—CO—NH-Q-R2Formula I:
Et-NH—CO—NH-Q-R2: Formula (II)
Et-NH—CO—NH—(CH2)3—NR6R7: Formula (III)
Me2N—(CH2)3—NH—CO—NH-Q-R2. Formula (IV)
14 Citations
10 Claims
-
1. A compound of formula I:
-
R1—
NH—
CO—
NH-Q-R2
(I)or a pharmaceutically acceptable salt thereof wherein R1 s a lower C2–
C5 alkyl group, straight or branched chain and optionally substituted by an amino group of formula —
NR3R4, wherein R3 and R4 are independently H, or C1–
C3 alkyl group;Q is either a bond or a divalent C1–
C5 straight or branched alkyl or aikenyl group;R2 is one of the following groups a. C5–
C10 heteroaryl group selected from furanyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, dithiolyl, oxathiolyl, isoxazolyl, piridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoquinolinyl, benzimidazolyl, benzoxaziyl, benzothiadiazolyl nanhthyridinyl, pyrido[3,4-b]pyridinyl, pyrido[3,2-b]b pyridinyl, pyrido[4,3-b]hyridinyl, and 4-aminopyrazolo[3,4d]pyrimidinylb. C5–
C10 heterocyclic group selected from piperazyl, tetahydrofuranyl, dioxanyl, wherein the heteroaryl, or heterocyclic ring is unsubstituted or substituted by one or more of the following groupsi. R5, —
CN, Halogen, OR5, —
COR5, —
CO2R5, OCF3, —
CONH2, —
SO2NH2, and NO2, wherein R5 is a C1 to C4 straight or branched alkyl group, andc. N6R 7, wherein R6 and R7 are together with the N forming a 5 or 6 membered monocyclic ring having one or more ring positions occupied by another N, S, or O, wherein the heteroaryl ring thus formed is unsubstituted or substituted by one or more of the following groups 1. R5, —
CN, halogen, OR5, —
COR5, —
CO2R5, OCF3, —
CONH2, —
SO2NH2,2. C1–
C5 aikyl or alkylene group substituted by an aryl group, and3. C6 or C10 aryl or heteroaryl group unsubstituted or substituted by one ore more of R5, CF3, and halogen, wherein the aryl or hetero aryl may be a pending group off one position of, or a fused with, the NR6R7 ring. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
6. The compound of claim 1 having the structure of
-
7. The compound of claim 1 having the structure of
-
8. A method of treating an inflammatory cond Won or disease by administering an effective amount of a compound of any one of the preceding claim in a pharmaceutically acceptable carrier.
-
9. The method of claim 8, wherein the condition is inflammatory bowel disease, autoimmune encephalomyelitis, lupus, or sepsis.
-
10. The method of claim 8, wherein the carrier is buffered saline.
-
Specification